Inhibition of cathepsin L sensitizes human glioma cells to ionizing radiation in vitro through NF-κB signaling pathway

Neng YANG#, Pan WANG#, Wen-juan WANG, Yun-zhen SONG, Zhong-qin LIANG*

Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China

Aim: Cathepsin L, a lysosomal cysteine proteinase, is exclusively elevated in a variety of malignancies, including gliomas. In this study we investigated the relationship between cathepsin L and NF-κB, two radiation-responsive elements, in regulating the sensitivity of human glioma cells ionizing radiation (IR) in vitro.

Methods: Human glioma U251 cells were exposed to IR (10 Gy), and the expression of cathepsin L and NF-κB was measured using Western blotting. The nuclear translocation of NF-κB p65 and p50 was analyzed with immunofluorescence assays. Cell apoptosis was examined with clonogenic assays. NF-κB transcription and NF-κB-dependent cyclin D1 and ATM transactivation were monitored using luciferase reporter and ChIP assays, respectively. DNA damage repair was investigated using the comet assay.

Results: IR significantly increased expression of cathepsin L and NF-κB p65 and p50 in the cells. Furthermore, IR significantly increased the nuclear translocation of NF-κB, and NF-κB-dependent cyclin D1 and ATM transactivation in the cells. Knockdown of p65 did not change the expression of cathepsin L in IR-treated cells. Pretreatment with Z-FY-CHO (a selective cathepsin L inhibitor), or knockdown of cathepsin L significantly attenuated IR-induced nuclear translocation of NF-κB and cyclin D1 and ATM transactivation, and sensitized the cells to IR. Pretreatment with Z-FY-CHO, or knockdown of p65 also decreased IR-induced DNA damage repair and clonogenic cell survival, and sensitized the cells to IR.

Conclusion: Cathepsin L acts as an upstream regulator of NF-κB activation in human glioma cells and contributes to their sensitivity to IR in vitro. Inhibition of cathepsin L can sensitize the cells to IR.

Keywords: glioma; radiotherapy; ionizing radiation; cathepsin L; cyclin D1; ATM; Z-FY-CHO; shRNA; DNA damage; clonogenic survival

Introduction

Radiotherapy is commonly used in cancer management, with 40%–60% of all cancer patients receiving radiation treatment[1]. Radiotherapy is considered mandatory for glioblastoma patients[2]. However, the development of radioresistance remains a significant therapeutic hindrance and limits the effectiveness of ionizing radiation (IR) in treating patients with glioma[3-9].

The stress-inducible transcription factor nuclear factor (NF)-κB regulates genes involved in an array of physiological and pathological processes, including cell cycle control, proliferation, cell growth, metastasis, inflammation, apoptosis, and oncogenic activation of human cancers; it has also been implicated as a determinant of radiosensitivity[4, 5]. NF-κB is the heterodimeric complex of Rel family proteins (p65, p50, p52, c-Rel, and RelB) that interacts with the inhibitor of κB (IκB) proteins in the cytoplasm. The active complex of NF-κB is composed of two subunits: p65 and p50[6-7]. When the canonical NF-κB pathway is stimulated, several signaling cascades converge at IKK, the inhibitor of the kappa-B kinase complex, which phosphorylates and degrades IκBα, thereby promoting the nuclear translocation of NF-κB to activate the expression of specific target genes[8]. NF-κB activity is known to be induced by IR in human glioma cells[9, 10]. Aberrant NF-κB activation contributes to radioresistance[11, 12], and the loss or inhibition of NF-κB has been shown to sensitize many different tumor types to IR[13-15]. NF-κB is known to be an important mechanism for conferring resistance to radiotherapy. There is also increasing evidence that inhibiting NF-κB is an attractive target for cancer therapeutics[16].

Cathepsin L (CTSL), a lysosomal cysteine proteinase, is
reported to be upregulated in a variety of malignancies: breast, lung, gastric, colon, head and neck carcinomas, melanomas, and gliomas\textsuperscript{[17–19]}. Research supports the notion that increased cathepsin L expression is involved in tumor progression, including cell apoptosis and cell cycle, because it is able to degrade nuclear transcription factors\textsuperscript{[20, 21]}. Cathepsin L is a survival protein that confers resistance to cancer cell apoptosis\textsuperscript{[22, 23]}. The expression of cathepsin L is exclusively elevated in cancer cells and can be easily screened for small-molecule inhibitors\textsuperscript{[24, 25]}; therefore, it may serve as a better therapeutic target than other cathepsins\textsuperscript{[26–28]}.

We have recently proven that the inhibition of cathepsin L can block the nuclear translocation of NF-κB in neuroblastoma cells\textsuperscript{[29]} and, furthermore, that cathepsin L contributes to quinolinic acid (QA)-induced NF-κB activation in rat striatal neurons\textsuperscript{[30]}. Ongoing work in our laboratory indicates that IR increases cathepsin L expression and that it is involved in the radiosensitivity of glioma cells. The results presented here lead us to hypothesize that cathepsin L can regulate radiation-induced NF-κB activation. To further investigate the relationship between these two radiation-responsive elements in tumor cells and to determine a possible mechanism regulating their modulation, cathepsin L and NF-κB were each inhibited to determine the effect on each other and on the radiosensitization of U251 cells.

**Materials and methods**

**Cell lines**

U251 human glioma cells were cultured in DMEM medium (Gibco Life Technologies, Paisley, UK) supplemented with 10% fetal bovine serum (Gibco Life Technologies).

**Antibodies and reagents**

Cathepsin L inhibitor II (Z-FY-CHO) was purchased from Calbiochem (La Jolla, CA, USA). Rabbit anti-NF-κB p65-ChIP antibodies and monoclonal mouse anti-cathepsin L antibodies were purchased from Abcam (Cambridge, UK). Polyclonal rabbit anti-p65 antibodies and a polyclonal rabbit IκBα antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal mouse anti-β-actin antibody and rabbit anti-lamin B antibody were purchased from MultiSciences (MultiSciences Biotech Co, Shanghai, China). Monoclonal mouse anti-p50 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

**shRNA transfection**

Human cathepsin L shRNA, NF-κB p65 shRNA and control shRNA were purchased from Santa Cruz Biotechnology. One day before transfection, U251 cells were seeded in six-well plates and grown in 2 mL of DMEM supplemented with 10% FBS. After 24 h in culture, shRNA plasmid DNA was transfected into cells with an shRNA Transfection Reagent kit according to the manufacturer’s protocol, and the cells were then subjected to different treatments. Cells were lysed and protein extracts were isolated and utilized to detect cathepsin L, NF-κB, and β-actin expression by Western blot analysis as described below.

**Western blotting**

Cells were seeded in DMEM containing 10% FBS for 24 h. Cells were then lysed in 50 mmol/L HEPES (pH 7.4), 150 mmol/L NaCl, 100 mmol/L NaF, 1 mmol/L MgCl\(_2\), 1.5 mmol/L EGTA, 10% glycerol, 1% Triton X-100, 1 g/mL leupeptin, and 1 mmol/L PMSF. Equal quantities of protein (40 μg) were separated by electrophoresis on a 12% SDS-PAGE gel and transferred to 0.45 μm nitrocellulose transfer membranes. The expression of cathepsin L, p65, p50, IκBα, β-actin and lamin B were identified by a reaction with specific primary antibodies (as described above) for 15 h, followed by washing 3 times with TBST and incubation for 1 h with secondary antibodies. After washing 3 times with TBST, reactive bands were detected by the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA).

**Immunofluorescence assay**

The localization of NF-κB protein in U251 cells was investigated using the immunofluorescence-staining assay. Cells were grown on glass disks in 24-well plates and then treated with either 10 Gy irradiation, 12 h incubation with 10 μmol/L Z-FY-CHO/shRNA cathepsin L or a combination of these two treatments. At 24 h after treatment, the glass disks were removed from the wells, washed with PBS, and fixed with cold methanol. After blocking with 1% BSA, the cells were incubated with rabbit anti-NF-κB antibody followed by an anti-rabbit secondary fluorescent antibody. Cells were then stained with DAPI in the dark. Images were captured using a laser scanning TCS SP2 confocal microscope (Leica).

**Luciferase reporter gene assay**

The pGL4.32 [luc2P/NF-κB-RE/Hygro] vector (a–f) contains five copies of an NF-κB response element (NF-κB-RE) that drives the transcription of the luciferase reporter gene luc2P (Photinus pyralis). Cells were seeded in 24-well plates and incubated for 24 h. The next day, the cells were transiently cotransfected with the promoter sequence-inserted luciferase pGL4.32 [luc2P/NF-κB-RE/Hygro] vector and the control pRL-TK vector (Promega, Madison, WI, USA) with Lipo- vectamine 2000 reagent (Invitrogen, NY, USA) 12 h before IR. Luciferase activity of the transfected cells was assayed using a dual-luciferase reporter assay kit (Promega) and luminometer (Infinite M200 plate counter, Tecxan, Männedorf, Switzerland). Relative luciferase activity was presented as the ratio of firefly units to renilla units.

**Chromatin immunoprecipitation (ChIP) assay**

U251 cells were cultured for 24 h before treatment with IR. Soluble chromatin was crosslinked by adding it to formaldehyde at 37°C for 10 min. Chromatin was sheared by sonication, and DNA fragments with sizes between 0.2 and 0.7 kb were obtained. Immune complexes were immunoprecipitated using anti-p65 or an IgG control antibody. Protein–DNA cross-links were then reverted at 65°C overnight. DNA was
purified and then subjected to PCR with primers specific for the gene promoter region encompassing the NF-κB binding site. Sequences of promoter-specific primers are as follows: GAPDH, 5'-GGACTCATGCCACGTCCAT-3' (forward) and 5'-GGTCACTCAGGATGCCC-3' (reverse); Cyclin D1, 5'-TCAAGGATGGTTTGG-3' (forward) and 5'-CAAATCAAAACTCCC-3' (reverse); ATM, 5'-GCACTTTAAGCTTCTTGTAG-3' (forward) and 5'-CCTGACTTTCTGCCAAT-3' (reverse).

**Comet assay**

DNA damage at the individual cell level following IR treatment was quantified using an alkaline comet assay. Cell suspensions were mixed with low melting point agarose, embedded onto a frosted glass slide pre-coated with a 0.8% layer of normal melting point agarose, allowed to gel at 4°C, gently topped with another 0.8% normal melting point agarose layer and covered with a coverslip. After the gel solidified, the coverslip was removed. Following lysis, slides were washed and subjected to electrophoresis under alkaline conditions at 20 V for 40 min. They were then fixed, dried, and stained with 50 μL of 5 mg/L ethidium bromide. An Olympus CKX31 fluorescence microscope (10×objective) was used to capture images. Comet data were collected by visual scoring. Subsequent time points are expressed as a percentage of the 0 time point.

**Radiation treatment and clonogenic survival assay**

Cells were seeded in six-well plates at a density of 2×10^2 cells per well. After an overnight incubation, the cells were pre-treated with 10 μmol/L Z-FY-CHO or cathepsin L shRNA/p65 shRNA for 12 h and exposed to different doses of IR. DNA damage was measured using low melting point agarose, allowed to gel at 4°C, gently topped with another 0.8% normal melting point agarose layer and covered with a coverslip. After the gel solidified, the coverslip was removed. Following lysis, slides were washed and subjected to electrophoresis under alkaline conditions at 20 V for 40 min. They were then fixed, dried, and stained with 50 μL of 5 mg/L ethidium bromide. An Olympus CKX31 fluorescence microscope (10×objective) was used to capture images. Comet data were collected by visual scoring. Subsequent time points are expressed as a percentage of the 0 time point.

**Statistical analysis**

Data expressed as the mean±SD. At least 3 independent experiments were performed. Differences in measured variables between the experimental and control groups were assessed by Student’s t-test. P values less than 0.05 were considered statistically significant. All analyses were performed with GraphPad Prism 5.0.

**Results**

**Increased protein expression of cathepsin L and nuclear translocation of NF-κB p65 and p50 in glioma U251 cells following IR**

To determine the effect of IR on cathepsin L expression and its role in determining IR sensitivity in cancer cells, we first examined the expression level of cathepsin L in whole cells at various time points following their exposure to IR. The treatment of U251 cells with IR caused a dose-dependent activation of cathepsin L as evidenced by Western blot analysis. The expression of cathepsin L (26 kDa) in U251 cells increased at approximately 30 min following exposure to IR (Figure 1A). Furthermore, clear nuclear translocation of IR-induced cathepsin L was observed (Figure 1B). The stimulative effect of IR on NF-κB activation was also verified by Western blot analysis. NF-κB nuclear protein was demonstrably increased in tumor cells treated with IR. IR activated both NF-κB p65 and p50 in U251 cells in a time-dependent manner, reaching maximum activation at 2 h and returning to control levels by 8 h (Figure 1C). Moreover, IR induced the nuclear translocation of p65 and p50 in U251 cells in a dose-dependent manner 2 h post-IR (Figure 1D). These results clearly show that IR activates cathepsin L and induces the nuclear translocation of NF-κB. However, whether cathepsin L is directly involved in the regulation of NF-κB remains to be explored. The maximum activation of NF-κB in U251 cells was at 2 h following IR (10 Gy); therefore, this IR dose and timepoint were chosen for the following experiments.

**Inhibition of cathepsin L sensitizes glioma U251 cells to IR**

To further determine the role of cathepsin L in IR sensitivity of tumor cells, we suppressed cathepsin L by using the inhibitor Z-FY-CHO or cathepsin L shRNA before subjecting the cells to a series of IR dosages. Colony-forming assays demonstrated that Z-FY-CHO sensitizes U251 cells to IR (Figure 2A). Next, cathepsin L expression in U251, U251-consh (cells transfected with control shRNA) and U251-Lsh (cells transfected with cathepsin L shRNA) cells confirmed the knockdown of cathepsin L expression (Figure 2B). U251-Lsh cells were more sensitive than U251-consh cells to IR (Figure 2C). Figure 2 demonstrates that the inhibition of cathepsin L in U251 cells augmented the colony-inhibiting effect of IR. These results indicate that IR-stimulated cathepsin L has a protective role in tumor cells, contributing to their growth, survival, and resistance to radiotherapy.

**Inhibition of cathepsin L using Z-FY-CHO or cathepsin L shRNA reduced IR-induced nuclear translocation of NF-κB**

Because cathepsin L was shown to have a prosurvival role in tumor cells treated with IR (Figure 1 and 2), we wanted to determine whether there was an association between the function of cathepsin L and the activity of NF-κB in the radioresistance of U251 cells. As shown above, nuclear translocation of p65 and p50 in U251 cells increased 2 h post-IR (10 Gy), while IR-induced activation of p65 and p50 in U251 cells was partially blocked by Z-FY-CHO (Figure 3A). The effect of Z-FY-CHO on IR-induced nuclear translocation of p65 was more clearly observed by immunofluorescence (Figure 4A). Parallel changes in NF-κB activation, the partial degradation of IκBα by IR was also reduced using Z-FY-CHO (Figure 3A). Similarly, IR-induced activation of NF-κB in U251-Lsh cells was less evident than in U251-consh cells (Figure 3B). Consistent with the altered p65 and p50 activation, IR triggered less degradation of IκBα in U251-Lsh cells compared to U251-consh cells (Figure 3C). These data indicate that cathepsin L plays such a critical role in the IR-induced activation of NF-κB.

**Inhibition of NF-κB activity**

Because cathepsin L was shown to have a prosurvival role in tumor cells treated with IR (Figure 1 and 2), we wanted to determine whether there was an association between the function of cathepsin L and the activity of NF-κB in the radioresistance of U251 cells. As shown above, nuclear translocation of p65 and p50 in U251 cells increased 2 h post-IR (10 Gy), while IR-induced activation of p65 and p50 in U251 cells was partially blocked by Z-FY-CHO (Figure 3A). The effect of Z-FY-CHO on IR-induced nuclear translocation of p65 was more clearly observed by immunofluorescence (Figure 4A). Parallel changes in NF-κB activation, the partial degradation of IκBα by IR was also reduced using Z-FY-CHO (Figure 3A). Similarly, IR-induced activation of NF-κB in U251-Lsh cells was less evident than in U251-consh cells (Figure 3B). Consistent with the altered p65 and p50 activation, IR triggered less degradation of IκBα in U251-Lsh cells compared to U251-consh cells (Figure 3C). These data indicate that cathepsin L plays such a critical role in the IR-induced activation of NF-κB.
that it could be a mediator of NF-κB-mediated radioresistance in U251 cells.

**Z-FY-CHO and cathepsin L shRNA inhibit IR-induced NF-κB dependent transcriotional activation**

We investigated the ability of p65 to bind its consensus sequence in U251 cells, U251-consh and U251-Lsh cells following IR using a luciferase-reporter assay. IR did not influence the expression of the internal control plasmid used to monitor transfection efficiency (data not shown). Consistent with increased DNA binding, the luciferase expression in U251 cells increased following IR and could be partially blocked by Z-FY-CHO (Figure 5A). Similarly, luciferase expression post-IR in U251-consh cells was higher than in U251-Lsh cells (Figure 5B). ChIP analysis was used to determine whether radiation-induced NF-κB enhances its downstream target genes Cyclin D1 and ATM. The recruitment of p65 to both the Cyclin D1 promoter (Figure 5C) and ATM promoter (Figure 5D) was significantly enhanced in U251-consh cells after exposure to IR compared to U251-Lsh cells, as expected. Thus, inhibition of cathepsin L blocked the activation and transcription of NF-κB in U251 cells treated with IR. In these experiments, suppression of cathepsin L by Z-FY-CHO or cathepsin L shRNA in IR-treated cells suggests that cathepsin L plays a key role in the regulation of IR-induced NF-κB transcriptional activity.
NF-κB inhibition sensitizes U251 cells to IR without affecting cathepsin L

After showing that cathepsin L is required for the expression and translocation of NF-κB in IR-treated cells (Figures 3, 4 and 5), we next determined the effect of NF-κB on cathepsin L. p65 expression analysis in U251 cells, U251-consh and U251-p65sh cells confirmed the efficiency of p65 knockdown (Figure 6A). An increase in cathepsin L expression (26 kDa) could be observed starting 30 min after IR exposure (Figure 1A). Thus, we compared the expression of cathepsin L in U251-p65sh (cells transfected with p65 shRNA) and U251-consh cells 30 min following control or IR exposure; no obvious change between these two types of cells was observed (Figure 6B). This suggests that p65 knockdown has no evident effect on the expression of cathepsin L (26 kDa). These results suggest that, in IR-treated U251 cells, cathepsin L acts as an upstream regulator of NF-κB activation. The alkaline comet assay was used to examine IR-induced single-strand break (SSB) formation and repair at the individual cell level (Figure 6C). Clonogenic assays also showed that reduced NF-κB expression is correlated with radiation-induced apoptosis, thereby sensitizing U251 cells to IR (Figure 7). These results provide evidence that direct inhibition of cathepsin L in U251 cancer cells is capable of enhancing radiation-induced cell death through the NF-κB signaling pathway.

Discussion

This study determined that cathepsin L acts as a regulator of NF-κB during radiotherapy of U251 cells. The expression of cathepsin L (26 kDa) and nuclear translocation of NF-κB increased significantly after exposure to IR in U251 cells. Additionally, in line with our hypothesis, the expression of cathepsin L increased prior to the nuclear translocation of NF-κB.
To investigate whether cathepsin L is involved in the activation of NF-κB, we reduced cathepsin L expression by treating U251 cells with the selective cathepsin L inhibitor Z-FY-CHO 12 h prior to radiation, or by transfecting the U251 cells with cathepsin L shRNA to establish a stable, low cathepsin L-expressing cell line using hygromycin selection. IR-induced nuclear translocation of NF-κB was reduced when the expression of cathepsin L was decreased based on Western blotting and immunofluorescence assays. NF-κB-dependent transcriptional activation was impaired in U251 cells following IR as measured by a dual-luciferase reporter assay. Furthermore, results of ChIP assays are congruent with the hypothesis that the inhibition of cathepsin L blocks the binding activity of NF-κB to its target genes Cyclin D1 and ATM following IR. The inhibition of cathepsin L increased the radiosensitivity of U251 cells to IR by reducing IR-induced DNA damage repair and clonogenic cell survival. Altogether, the above data demonstrate that the inhibition of cathepsin L reduces radiation-induced NF-κB activation, which is involved in radioresistance, thereby improving the sensitivity of U251 cells to ionizing radiation.

Some studies have discovered a regulatory loop in which cathepsin L acts as a downstream target gene of NF-κB in murine C2C12 cells. In this model, cathepsin L is downregulated when IκBβ was silenced[31, 32]. These studies were focused on NF-κB-mediated modulation of cathepsin L, but cathepsin
L-mediated modulation of the NF-κB signaling pathways has not been well studied. Thus, the interaction between cathepsin L and NF-κB remains unclear.

Here, we demonstrated a relationship between cathepsin L and NF-κB, confirming that cathepsin L affects the radiosensitivity of U251 cells via the regulation of NF-κB signaling. We established NF-κB knockdown U251 cell lines by using p65 shRNA. Unsurprisingly, no distinction in the basal expression level of cathepsin L was observed between U251-p65sh cells and irradiated or control RNA transfected cells, which means that the inhibition of NF-κB had no significant impact on the expression of cathepsin L in U251 cells.

To further understand cathepsin L’s mechanism of action, we tested the extent of DNA damage following IR. The results of alkaline comet assays and clonogenic cell survival experiments suggested that IR-induced DNA damage repair and clonogenic cell survival in U251 cells were significantly decreased when NF-κB was inhibited, respectively, implying increased radiosensitivity of U251 cells; however, there was no notable difference between irradiated and nonirradiated U251-p65sh cells at the level of DNA damage repair or clonogenic cell survival. Thus, we observed that NF-κB is closely related to radioresistance but has little impact on the expression of cathepsin L in U251 cells.

However, studies working to elucidate the exact mechanisms involved in cathepsin L regulation of NF-κB pathway regulation are still needed. Further understanding of how the cathepsin L pathway works may provide new insights into the cancer process. Because the activity of NF-κB is tightly regulated by interaction with inhibitory IκB proteins, it is presumed that cathepsin L is involved in the proteolysis of IκB, which in turn accelerates the activation of NF-κB. Moreover, active cathepsin L (26 kDa) can translocate to the nucleus to mediate the proteolytic processing of CUX1 to generate p110 CUX1, which is the active form of full-length p200 CUX1. CUX1 plays an important role in the transcriptional regulation of chemotactic factors that are mediated by NF-κB. CUX1 regulates ATM expression in response to DNA damage by binding to the promoter of the DDR gene ATM; this demonstrates that CUX1 is required for ATM-/ATR-mediated cellular responses to genotoxic stress following IR exposure. Cathepsin L most likely regulates the activity of NF-κB and its downstream effectors via the CUX1 pathway.

It is likely that cathepsin L participates in NF-κB mediated radioresistance through several other correlating mechanisms to mediate CUX1 as well. For instance, β-Catenin, a key medi-
ator in the Wnt pathway, is a novel target of CUX1\textsuperscript{[37, 38]}. Differential crosstalk exists between β-catenin/Tcf and the NF-κB pathway in various cancer types, which has implications on the mechanism described above\textsuperscript{[39]} and provides a mechanistic link between the Wnt cascade and NF-κB activation\textsuperscript{[40]}.

Some articles have posited that cathepsin L is conditionally regulated by NF-κB when the cells were in mitochondrial respiratory stress\textsuperscript{[31, 32]}. However, we recently found the opposite regulatory mechanism—that cathepsin L contributes to NF-κB activation in the presence of quinolinic acid in rat striatal neurons. How these signals respond to radiation may vary under different conditions. Thus, it is reasonable for us to speculate that cathepsin L could also act on nuclear transcriptional factors and then regulate the activity of NF-κB either directly or indirectly.

The interaction between the NF-κB and cathepsin L pathways occurs at multiple cellular levels. The results of our study show that the modulation of the cathepsin L signaling pathway affects NF-κB signaling in U251 cells. Cathepsin L most likely has other interaction partners and functions in a complex network to regulate NF-κB pathways. In this report, we present a new interaction modality for the two radio-asso-
In summary, our study identified that cathepsin L plays an important role in mediating NF-κB activation and contributes to radioresistance in U251 cell lines. The inhibition of cathepsin L can reduce NF-κB activation to enhance IR-induced cytotoxicity, which makes it a potential target for tumor radiotherapy.

Figure 6. Effect of p65 shRNA on the expression of p65 and cathepsin L in U251 and MCF-7 cells. (A) Western blot of p65 whole cell extracts from normal U251, U251-consh and U251-p65sh cells. β-Actin was used as an internal control. ①P<0.01 vs U251. ②P<0.01 vs U251-consh. (B) Western blot analysis of cathepsin L in U251-consh and U251-p65sh cells 30 min following control or X-ray (10 Gy) treatment. (C) Representative images of alkaline comet assay and the quantification of the percentages of cells with comet tails in U251-consh and U251-p65sh cells treated with radiation (10 Gy) alone or in combination with Z-FY-CHO. ①P<0.05, ②P<0.01 vs U251-consh group at the relative time points.
radiation (0, 2, 4, 6, and 8 Gy) alone or in combination with Z-FY-CHO.

Figure 7. Clonogenic survival curves for U251-p65sh cells treated with radiation (0, 2, 4, 6, and 8 Gy) alone or in combination with Z-FY-CHO.

Acknowledgements
This study was supported by grants from the National Natural Science Foundation of China (Grant No 81072656, 81102466, and 81373430) and the Priority Academic Program Development (PAPD) of the Jiangsu Higher Education Institutions (Key Medical Department of Jiangsu Province in 2011).

Author contribution
Zhong-qin LIANG designed research; Neng YANG, Wen-juan WANG, and Yun-zhen SONG performed research; Neng YANG analyzed data; Neng YANG and Pan WANG wrote the paper.

References
1. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 2007; 67: 3845–52.
2. Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D, et al. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 2008; 68: 7570–8.
3. Madhusoodhanan R, Natarajan M, Veeraraghavan J, Herman TS, Aravindan N. NF-kappaB activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation. Cancer Biol Ther 2009; 8: 158–69.
4. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005; 123: 158–69.
5. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
6. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor kappaB. J Clin Invest 1993; 88: 691–5.
7. Russel JS, Raju U, Gumin GJ, Lang FF, Wilson DR, Huet T, et al. Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res 2002; 62: 2318–26.
8. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor kappaB. J Clin Invest 1993; 88: 691–5.
9. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor kappaB. J Clin Invest 1993; 88: 691–5.
10. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005; 123: 158–69.
11. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor kappaB. J Clin Invest 1993; 88: 691–5.
12. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor kappaB. J Clin Invest 1993; 88: 691–5.
13. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
14. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
15. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
16. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
17. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
18. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
19. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
20. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
21. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
22. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
23. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
24. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Clin Invest 1993; 88: 691–5.
plays a role in quinolinic acid-induced NF-Kappab activation and excitotoxicity in rat striatal neurons. PLoS One 2013; 8: e75702.

31 Biswas G, Tang W, Sondheimer N, Guha M, Bansai S, Avadhani NG. A distinctive physiological role for IkappaBbeta in the propagation of mitochondrial respiratory stress signaling. J Biol Chem 2008; 283: 12586–94.

32 Guha M, Fang JK, Monks R, Birnbaum MJ, Avadhani NG. Activation of Akt is essential for the propagation of mitochondrial respiratory stress signaling and activation of the transcriptional coactivator heterogeneous ribonucleoprotein A2. Mol Biol Cell 2010; 21: 3578–89.

33 Goulet B, Nepveu A. Complete and limited proteolysis in cell cycle progression. Cell Cycle 2004; 3: 986–9.

34 Fragiadaki M, Ikeda T, Witherden A, Mason RM, Abraham D, Bou-Gharios G. High doses of TGF-beta potently suppress type I collagen via the transcription factor CUX1. Mol Biol Cell 2011; 22: 1836–44.

35 Ueda Y, Su Y, Richmond A. CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res 2007; 17: 91–103.

36 Vadnais C, Davoudi S, Afshin M, Harada R, Dudley R, Clermont PL, et al. CUX1 transcription factor is required for optimal ATM/ATR-mediated responses to DNA damage. Nucleic Acids Res 2012; 40: 4483–95.

37 Ripka S, Konig A, Buchholz M, Wagner M, Sipos B, Kloppel G, et al. WNT5A--target of CUTF1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 2007; 28: 1178–87.

38 Katoh M. Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med 2009; 23: 763–9.

39 Cho HH, Song JS, Yu JM, Yu SS, Choi SJ, Kim DH, et al. Differential effect of NF-kappa B activity on beta-catenin/Tcf pathway in various cancer cells. FEBS Lett 2008; 582: 616–22.

40 Wang X, Adhikari N, Li Q, Guan Z, Hall JL. The role of [beta]-transducin repeat-containing protein (beta-TrCP) in the regulation of NF-kappaB in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 85–90.